Literature DB >> 19451064

Characteristics and outcome of prostate cancer with PSA <4 ng/ml at diagnosis: a population-based study.

M Bonet1, A Merglen, G Fioretta, E Rapiti, I Neyroud-Caspar, R Zanetti, R Miralbell, C Bouchardy.   

Abstract

This population-based study aims to assess prognosis of prostate cancer diagnosed with prostate-specific antigen (PSA) levels <4 ng/ml in routine care. Materials and methods We compared prostate cancer patients with low PSA values (n=59) with other prostate cancer patients (n=1330) by logistic regression and the Cox model using data from the Geneva Cancer Registry. Results Patients with low PSA values more frequently had early-stage and well differentiated tumours. Nevertheless, 35% presented with aggressive tumour characteristics or metastases. After adjustment for other prognostic factors, prostate cancer-specific mortality was similar for both groups (hazard ratio: 1.1; 95%CI: 0.6-2.2). Conclusion We conclude that cancer with low PSA values at diagnosis is not indolent.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19451064     DOI: 10.1007/s12094-009-0359-1

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  34 in total

1.  The importance of marital and socioeconomic status in incidence and survival of prostate cancer. An analysis of complete Norwegian birth cohorts.

Authors:  S Harvei; O Kravdal
Journal:  Prev Med       Date:  1997 Sep-Oct       Impact factor: 4.018

2.  Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)--Section Rotterdam. A comparison of two rounds of screening.

Authors:  Renske Postma; Fritz H Schröder; Geert J L H van Leenders; Robert F Hoedemaeker; Andre N Vis; Monique J Roobol; Theodorus H van der Kwast
Journal:  Eur Urol       Date:  2007-01-16       Impact factor: 20.096

3.  Preoperative PSA and progression-free survival after radical prostatectomy for Stage T1c disease.

Authors:  Jo Ann V Antenor; Kimberly A Roehl; Scott E Eggener; Shilajit D Kundu; Misop Han; William J Catalona
Journal:  Urology       Date:  2005-07       Impact factor: 2.649

4.  Survival in prostate carcinoma--outcomes from a prospective, population-based cohort of 8887 men with up to 15 years of follow-up: results from three countries in the population-based National Prostate Cancer Registry of Sweden.

Authors:  Gunnar Aus; David Robinson; Johan Rosell; Gabriel Sandblom; Eberhard Varenhorst
Journal:  Cancer       Date:  2005-03-01       Impact factor: 6.860

5.  Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.

Authors:  W J Catalona; D S Smith; D K Ornstein
Journal:  JAMA       Date:  1997-05-14       Impact factor: 56.272

6.  Lower prostate specific antigen outcome than expected following radical prostatectomy in patients with high grade prostate and a prostatic specific antigen level of 4 ng/ml. Or less.

Authors:  Anthony V D'Amico; Ming-Hui Chen; S Bruce Malkowicz; Richard Whittington; Andrew A Renshaw; John E Tomaszewski; Yelina Samofalov; Alan Wein; Jerome P Richie
Journal:  J Urol       Date:  2002-05       Impact factor: 7.450

7.  Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.

Authors:  P Kupelian; J Katcher; H Levin; C Zippe; E Klein
Journal:  Urology       Date:  1996-08       Impact factor: 2.649

8.  Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease.

Authors:  H B Carter; J I Epstein; A W Partin
Journal:  Urology       Date:  1999-01       Impact factor: 2.649

9.  Radiation therapy for T1 and T2 prostate cancer: prostate-specific antigen and disease outcome.

Authors:  G K Zagars; A Pollack
Journal:  Urology       Date:  1995-03       Impact factor: 2.649

10.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Authors:  Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245

View more
  3 in total

1.  Prolonged remission of fulminant castrate-resistant prostate cancer: a case report.

Authors:  Mehmet Asim Bilen; Rosale General; Shi-Ming Tu
Journal:  Clin Genitourin Cancer       Date:  2011-05-14       Impact factor: 2.872

2.  An Advanced but Traditional Technique of Transurethral Resection of the Prostate in Order not to Overlook Stage T1 Prostate Cancer.

Authors:  Masaru Morita; Takeshi Matsuura
Journal:  Curr Urol       Date:  2012-04-30

3.  A comparative population-based study of prostate cancer incidence and mortality rates in Singapore, Sweden and Geneva, Switzerland from 1973 to 2006.

Authors:  Cynthia Chen; Nasheen Naidoo; Qian Yang; Mikael Hartman; Helena M Verkooijen; En Yun Loy; Christine Bouchardy; Kee Seng Chia; Sin Eng Chia
Journal:  BMC Cancer       Date:  2012-06-06       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.